Truist Securities Maintains Buy on Sutro Biopharma, Lowers Price Target to $18
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 03 2024
0mins
Should l Buy STRO?
Source: Benzinga
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STRO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STRO
Wall Street analysts forecast STRO stock price to fall
7 Analyst Rating
4 Buy
2 Hold
1 Sell
Moderate Buy
Current: 24.910
Low
8.00
Averages
20.00
High
51.00
Current: 24.910
Low
8.00
Averages
20.00
High
51.00
About STRO
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SUTRO BIOPHARMA INC.: WELLS FARGO INCREASES TARGET PRICE FROM $8 TO $27
- Stock Price Increase: Sutro Biopharma's stock price has risen significantly, increasing from $8 to $27.
- Market Reaction: The substantial rise in stock price indicates positive market sentiment towards Sutro Biopharma's performance or potential developments.
See More
Sutro Biopharma Reports 2025 Financial Results and Pipeline Updates
- Improved Financial Performance: Sutro Biopharma reported a narrowed net loss of $191.18 million for FY25, translating to a loss of $22.49 per share, down from $225.10 million and $29.40 per share in the previous year, indicating progress in financial management.
- Significant Revenue Growth: The company's revenue surged from $62.04 million to $102.48 million, primarily driven by collaborations with Astellas and Ipsen, reflecting the effectiveness of its business model and increased market demand.
- R&D Progress on Track: The Phase 1 trial of STRO-004 has dosed three cohorts, with initial data expected in mid-2026, while the IND submission for STRO-227 is also advancing, showcasing the company's commitment to innovative drug development.
- Milestone Payment Opportunities: Sutro's collaboration with Astellas includes a TROP2-targeted program that has entered clinical trials, potentially triggering a $10 million milestone payment in Q2 2026, while another program is in IND-enabling toxicology studies, expected to trigger a $7.5 million payment, enhancing the company's financial stability.
See More
Sutro Biopharma Receives Upgraded Rating
- Rating Information: Sutro Biopharma has an average rating of overweight, indicating analysts' optimistic outlook on its future performance, which may attract more investor attention.
- Price Target: The mean price target set by analysts is $27.38, suggesting significant upside potential compared to the current stock price, which could drive market demand for the stock.
- Market Reaction: This rating upgrade may enhance investor confidence, potentially increasing trading volume and impacting the stock price's short-term volatility.
- Strategic Significance: The analysts' positive rating reflects confidence in Sutro Biopharma's future product development and market performance, which could help the company attract more funding and resources to support its R&D activities.
See More
Sutro Biopharma Reports Disappointing Earnings Despite Revenue Growth
- Earnings Report: Sutro Biopharma's FY GAAP EPS of -$22.49 missed expectations by $7.28, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Growth: The company reported revenue of $102.48M, a 65.2% year-over-year increase, surpassing estimates by $3.3M, reflecting strong market demand for its products.
- Cash Flow Enhancement: Sutro strengthened its cash position with an underwritten offering of 7,868,383 shares at $13.98 per share, generating gross proceeds of $110 million, which is expected to extend its cash runway into at least Q2 2028.
- Strategic Outlook: The anticipated cash flow will support milestones from existing collaborations, and despite profitability challenges, Sutro aims for a positive transformation by 2026.
See More
Sutro Biopharma Participates in World ADC Summit
- Participation in World ADC Summit: Sutro Biopharma is participating in the 16th World ADC Summit in London from February 23-26, 2026, showcasing its innovations in antibody-drug conjugates (ADCs) to enhance its visibility and influence in the oncology market.
- Expert Panel Discussions: Chief Scientific Officer Hans-Peter Gerber, Ph.D., will participate in multiple panel discussions, including ADC licensing, partnering, and investment, which is expected to attract attention from industry stakeholders and foster relationships with potential partners.
- Showcasing Innovative Therapies: During the summit, Dr. Gerber will present on the efficacy and safety profiles of dual payload ADCs, particularly focusing on novel linker payloads to overcome resistance mechanisms, potentially piquing investor interest in Sutro's cutting-edge cancer therapies.
- Scientific Publications Release: Following the event, Sutro will publish the content from the discussions in the Scientific Publications section of its website, enhancing its influence in the scientific community and laying the groundwork for future research collaborations.
See More
Sutro Biopharma Prices 7.87M Share Offering at $13.98 Each
- Offering Size: Sutro Biopharma has priced an underwritten offering of 7.87 million shares of common stock at $13.98 per share, which is expected to generate approximately $110 million in gross proceeds before fees and expenses, thereby enhancing the company's financial strength for future growth.
- Use of Proceeds: The net proceeds from this offering will be used alongside existing cash primarily for general corporate purposes, including R&D, clinical development, manufacturing, working capital, and potential acquisitions or investments, aimed at advancing the company's strategic objectives.
- Market Reaction: Following the announcement of the offering, Sutro Biopharma's shares rose 4.5% in premarket trading, reflecting a positive market response to the company's financing plans, which may bolster investor confidence.
- Future Outlook: The closing of this stock offering is expected around February 11, 2026, marking a strategic reset for Sutro in its next-generation ADC pipeline and platform innovation, potentially opening new avenues for growth.
See More
SUTRO BIOPHARMA INC.: WELLS FARGO INCREASES TARGET PRICE FROM $8 TO $27
- Stock Price Increase: Sutro Biopharma's stock price has risen significantly, increasing from $8 to $27.
- Market Reaction: The substantial rise in stock price indicates positive market sentiment towards Sutro Biopharma's performance or potential developments.
See More
Sutro Biopharma Reports 2025 Financial Results and Pipeline Updates
- Improved Financial Performance: Sutro Biopharma reported a narrowed net loss of $191.18 million for FY25, translating to a loss of $22.49 per share, down from $225.10 million and $29.40 per share in the previous year, indicating progress in financial management.
- Significant Revenue Growth: The company's revenue surged from $62.04 million to $102.48 million, primarily driven by collaborations with Astellas and Ipsen, reflecting the effectiveness of its business model and increased market demand.
- R&D Progress on Track: The Phase 1 trial of STRO-004 has dosed three cohorts, with initial data expected in mid-2026, while the IND submission for STRO-227 is also advancing, showcasing the company's commitment to innovative drug development.
- Milestone Payment Opportunities: Sutro's collaboration with Astellas includes a TROP2-targeted program that has entered clinical trials, potentially triggering a $10 million milestone payment in Q2 2026, while another program is in IND-enabling toxicology studies, expected to trigger a $7.5 million payment, enhancing the company's financial stability.
See More
Sutro Biopharma Receives Upgraded Rating
- Rating Information: Sutro Biopharma has an average rating of overweight, indicating analysts' optimistic outlook on its future performance, which may attract more investor attention.
- Price Target: The mean price target set by analysts is $27.38, suggesting significant upside potential compared to the current stock price, which could drive market demand for the stock.
- Market Reaction: This rating upgrade may enhance investor confidence, potentially increasing trading volume and impacting the stock price's short-term volatility.
- Strategic Significance: The analysts' positive rating reflects confidence in Sutro Biopharma's future product development and market performance, which could help the company attract more funding and resources to support its R&D activities.
See More
Sutro Biopharma Reports Disappointing Earnings Despite Revenue Growth
- Earnings Report: Sutro Biopharma's FY GAAP EPS of -$22.49 missed expectations by $7.28, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Growth: The company reported revenue of $102.48M, a 65.2% year-over-year increase, surpassing estimates by $3.3M, reflecting strong market demand for its products.
- Cash Flow Enhancement: Sutro strengthened its cash position with an underwritten offering of 7,868,383 shares at $13.98 per share, generating gross proceeds of $110 million, which is expected to extend its cash runway into at least Q2 2028.
- Strategic Outlook: The anticipated cash flow will support milestones from existing collaborations, and despite profitability challenges, Sutro aims for a positive transformation by 2026.
See More
Sutro Biopharma Participates in World ADC Summit
- Participation in World ADC Summit: Sutro Biopharma is participating in the 16th World ADC Summit in London from February 23-26, 2026, showcasing its innovations in antibody-drug conjugates (ADCs) to enhance its visibility and influence in the oncology market.
- Expert Panel Discussions: Chief Scientific Officer Hans-Peter Gerber, Ph.D., will participate in multiple panel discussions, including ADC licensing, partnering, and investment, which is expected to attract attention from industry stakeholders and foster relationships with potential partners.
- Showcasing Innovative Therapies: During the summit, Dr. Gerber will present on the efficacy and safety profiles of dual payload ADCs, particularly focusing on novel linker payloads to overcome resistance mechanisms, potentially piquing investor interest in Sutro's cutting-edge cancer therapies.
- Scientific Publications Release: Following the event, Sutro will publish the content from the discussions in the Scientific Publications section of its website, enhancing its influence in the scientific community and laying the groundwork for future research collaborations.
See More
Sutro Biopharma Prices 7.87M Share Offering at $13.98 Each
- Offering Size: Sutro Biopharma has priced an underwritten offering of 7.87 million shares of common stock at $13.98 per share, which is expected to generate approximately $110 million in gross proceeds before fees and expenses, thereby enhancing the company's financial strength for future growth.
- Use of Proceeds: The net proceeds from this offering will be used alongside existing cash primarily for general corporate purposes, including R&D, clinical development, manufacturing, working capital, and potential acquisitions or investments, aimed at advancing the company's strategic objectives.
- Market Reaction: Following the announcement of the offering, Sutro Biopharma's shares rose 4.5% in premarket trading, reflecting a positive market response to the company's financing plans, which may bolster investor confidence.
- Future Outlook: The closing of this stock offering is expected around February 11, 2026, marking a strategic reset for Sutro in its next-generation ADC pipeline and platform innovation, potentially opening new avenues for growth.
See More
